

# Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Sanofi
<b>Enrollment</b>	60 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Male or female participants aged 18 years and older with a documented diagnosis of primary ITP in the medical history
- Participant received at least one course of first-line therapy and had a history of response while on treatment
- Participant has loss of response, relapse, or steroid dependency

### Exclusion (7)

- Participants with Secondary ITP
  - Participants with Evans syndrome or history of myelodysplastic syndrome
  - Participants with history of lymphoma, leukemia, or any malignancy within the past 5 years except for non-melanoma skin malignancy.
  - Participants with history of solid organ transplant
  - Participants with history of coagulation or bleeding disorders other than ITP, including genetic conditions, other than ITP
- ... and 2 more (see full listing online)

## Locations (20 total)

---

University of Michigan Health - Michigan Medicine - University Hospital-Investigational Site Number: 8400001, Ann Arbor, Michigan, United States  
Mayo Clinic\_Investigational Site Number: 8400009, Rochester, Minnesota, United States  
New York Oncology Hematology\_Investigational Site Number: 8400010, Albany, New York, United States  
... and 17 more locations